Literature DB >> 3048575

In vitro production of beta 2 microglobulin by human myeloma cells.

R Bataille1, J Grenier, T Commes.   

Abstract

Serum beta 2 microglobulin (B2M) has recently been shown to be a powerful, although nonspecific, marker of multiple myeloma (MM) disease activity. Since the nature of cells producing high levels of B2M remains obscure in MM, we measured (in vitro) the spontaneous secretion of free B2M in 58 culture samples from 52 patients with MM. In comparison with samples from normal individuals and from individuals with monoclonal gammopathy of unknown significance, an abnormal secretion of B2M was found in 83% of samples containing myeloma cells. Levels of secretion significantly correlated with the percentage of tumor cells, tumor progression, and moreover, with the immunoglobulin type of the tumor. The highest levels of secretion were noted in IgG and IgA MM. Our present results would favor the hypothesis of a direct secretion of B2M by myeloma cells and emphasize the interest of B2M as a marker in a majority of (but not all) patients with MM.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3048575     DOI: 10.3109/07357908809080649

Source DB:  PubMed          Journal:  Cancer Invest        ISSN: 0735-7907            Impact factor:   2.176


  4 in total

1.  Effect of interleukin-2 on the ex vivo growth of human myeloma cells.

Authors:  D Peest; I de Vries; R Hölscher; R Leo; H Deicher
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

2.  Androgen receptor survival signaling is blocked by anti-beta2-microglobulin monoclonal antibody via a MAPK/lipogenic pathway in human prostate cancer cells.

Authors:  Wen-Chin Huang; Haiyen E Zhau; Leland W K Chung
Journal:  J Biol Chem       Date:  2010-01-13       Impact factor: 5.157

3.  Nanotechnology for early cancer detection.

Authors:  Young-Eun Choi; Ju-Won Kwak; Joon Won Park
Journal:  Sensors (Basel)       Date:  2010-01-06       Impact factor: 3.576

4.  Enhanced expression of mRNA for nuclear factor kappaB1 (p50) in CD34+ cells of the bone marrow in rheumatoid arthritis.

Authors:  Shunsei Hirohata; Yasushi Miura; Tetsuya Tomita; Hideki Yoshikawa; Takahiro Ochi; Nicholas Chiorazzi
Journal:  Arthritis Res Ther       Date:  2006-03-06       Impact factor: 5.156

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.